State Street Global Advisors - advised funds > SPDR SERIES TRUST
SPDR(R) S&P(R) Biotech ETF
$6.56B
Avg Monthly Net Assets
$7.66B
Total Assets
$533.39M
Total Liabilities
$7.13B
Net Assets
SPDR(R) S&P(R) Biotech ETF is an Exchange-Traded Fund in SPDR SERIES TRUST
from State Street Global Advisors - advised funds,
based in Massachusetts,
United States of America.
The fund has one share class
and monthly net assets of $6.56B.
On August 28th, 2024 it reported 143 holdings, the largest
being State Street Global Advisors (7.5%), Sarepta Therapeutics Inc (3.3%) and United Therapeutics Corp (3.0%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Exchange | Ticker | Monthly Returns (2 years) |
|---|---|---|---|---|
| SPDR(R) S&P(R) Biotech ETF | C000027706 | ARCX | XBI |
Holdings
From latest NPORT-P, filed August 28th, 2024 for period ending June 30th, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | Long | Equity-common | US | $21M | 989K | 0.29 |
| 89bio Inc | Long | Equity-common | US | $12M | 1M | 0.17 |
| AbbVie Inc | Long | Equity-common | US | $195M | 1M | 2.74 |
| ACADIA Pharmaceuticals Inc | Long | Equity-common | US | $51M | 3M | 0.72 |
| ADMA Biologics Inc | Long | Equity-common | US | $32M | 3M | 0.45 |
| Agios Pharmaceuticals Inc | Long | Equity-common | US | $34M | 795K | 0.48 |
| Akero Therapeutics Inc | Long | Equity-common | US | $29M | 1M | 0.41 |
| Alector Inc | Long | Equity-common | US | $5M | 1M | 0.07 |
| Alkermes PLC | Long | Equity-common | IE | $72M | 3M | 1.01 |
| Allogene Therapeutics Inc | Long | Equity-common | US | $10M | 4M | 0.14 |
| Alnylam Pharmaceuticals Inc | Long | Equity-common | US | $204M | 839K | 2.86 |
| Altimmune Inc | Long | Equity-common | US | $15M | 2M | 0.21 |
| Amgen Inc | Long | Equity-common | US | $201M | 642K | 2.82 |
| Amicus Therapeutics Inc | Long | Equity-common | US | $47M | 5M | 0.66 |
| AnaptysBio Inc | Long | Equity-common | US | $13M | 514K | 0.18 |
| Anavex Life Sciences Corp | Long | Equity-common | US | $10M | 2M | 0.14 |
| Apellis Pharmaceuticals Inc | Long | Equity-common | US | $96M | 3M | 1.35 |
| Apogee Therapeutics Inc | Long | Equity-common | US | $30M | 774K | 0.43 |
| Arcellx Inc | Long | Equity-common | US | $49M | 888K | 0.69 |
| Arcturus Therapeutics Holdings Inc | Long | Equity-common | US | $20M | 807K | 0.28 |
| Arcus Biosciences Inc | Long | Equity-common | US | $15M | 991K | 0.21 |
| Arcutis Biotherapeutics Inc | Long | Equity-common | US | $25M | 3M | 0.35 |
| Ardelyx Inc | Long | Equity-common | US | $49M | 7M | 0.69 |
| Arrowhead Pharmaceuticals Inc | Long | Equity-common | US | $39M | 2M | 0.55 |
| ARS Pharmaceuticals Inc | Long | Equity-common | US | $8M | 926K | 0.11 |
| Astria Therapeutics Inc | Long | Equity-common | US | $10M | 1M | 0.15 |
| Avid Bioservices Inc | Long | Equity-common | US | $14M | 2M | 0.19 |
| Avidity Biosciences Inc | Long | Equity-common | US | $46M | 1M | 0.65 |
| Beam Therapeutics Inc | Long | Equity-common | US | $40M | 2M | 0.56 |
| BioCryst Pharmaceuticals Inc | Long | Equity-common | US | $30M | 5M | 0.42 |
| Biogen Inc | Long | Equity-common | US | $192M | 828K | 2.69 |
| Biohaven Ltd | Long | Equity-common | VG | $70M | 2M | 0.99 |
| BioMarin Pharmaceutical Inc | Long | Equity-common | US | $189M | 2M | 2.65 |
| Blueprint Medicines Corp | Long | Equity-common | US | $106M | 983K | 1.49 |
| Bridgebio Pharma Inc | Long | Equity-common | US | $71M | 3M | 1.00 |
| C4 Therapeutics Inc | Long | Equity-common | US | $9M | 2M | 0.12 |
| Cabaletta Bio Inc | Long | Equity-common | US | $8M | 1M | 0.11 |
| CareDx Inc | Long | Equity-common | US | $14M | 925K | 0.20 |
| Cargo Therapeutics Inc | Long | Equity-common | US | $7M | 412K | 0.09 |
| Catalyst Pharmaceuticals Inc | Long | Equity-common | US | $30M | 2M | 0.42 |
| Celldex Therapeutics Inc | Long | Equity-common | US | $46M | 1M | 0.64 |
| Cerevel Therapeutics Holdings Inc | Long | Equity-common | US | $78M | 2M | 1.09 |
| CG oncology Inc | Long | Equity-common | US | $17M | 527K | 0.23 |
| Cogent Biosciences Inc | Long | Equity-common | US | $16M | 2M | 0.23 |
| CONTRA INHIBRX INC | Derivative-equity | US | $1M | 2M | 0.02 | |
| CONTRA MIRATI THERAPEU | Derivative-equity | US | $959K | 1M | 0.01 | |
| Corbus Pharmaceuticals Holdings Inc | Long | Equity-common | US | $11M | 240K | 0.15 |
| Crinetics Pharmaceuticals Inc | Long | Equity-common | US | $52M | 1M | 0.73 |
| CRISPR Therapeutics AG | Long | Equity-common | CH | $102M | 2M | 1.43 |
| Cullinan Therapeutics Inc | Long | Equity-common | US | $19M | 1M | 0.27 |
| Cytokinetics Inc | Long | Equity-common | US | $147M | 3M | 2.06 |
| Day One Biopharmaceuticals Inc | Long | Equity-common | US | $21M | 2M | 0.30 |
| Denali Therapeutics Inc | Long | Equity-common | US | $36M | 2M | 0.51 |
| Disc Medicine Inc | Long | Equity-common | US | $11M | 248K | 0.16 |
| Dynavax Technologies Corp | Long | Equity-common | US | $36M | 3M | 0.51 |
| Dyne Therapeutics Inc | Long | Equity-common | US | $53M | 2M | 0.74 |
| Editas Medicine Inc | Long | Equity-common | US | $10M | 2M | 0.15 |
| Exact Sciences Corp | Long | Equity-common | US | $193M | 5M | 2.72 |
| Exelixis Inc | Long | Equity-common | US | $81M | 4M | 1.14 |
| Fate Therapeutics Inc | Long | Equity-common | US | $9M | 3M | 0.12 |
| Geron Corp | Long | Equity-common | US | $42M | 10M | 0.60 |
| Gilead Sciences Inc | Long | Equity-common | US | $202M | 3M | 2.84 |
| Halozyme Therapeutics Inc | Long | Equity-common | US | $71M | 1M | 1.00 |
| Heron Therapeutics Inc | Long | Equity-common | US | $9M | 3M | 0.13 |
| Humacyte Inc | Long | Equity-common | US | $5M | 1M | 0.07 |
| Ideaya Biosciences Inc | Long | Equity-common | US | $44M | 1M | 0.61 |
| ImmunityBio Inc | Long | Equity-common | US | $28M | 5M | 0.40 |
| Immunome Inc | Long | Equity-common | US | $15M | 1M | 0.20 |
| Immunovant Inc | Long | Equity-common | US | $38M | 1M | 0.54 |
| Incyte Corp | Long | Equity-common | US | $177M | 3M | 2.49 |
| Insmed Inc | Long | Equity-common | US | $78M | 1M | 1.09 |
| Intellia Therapeutics Inc | Long | Equity-common | US | $48M | 2M | 0.68 |
| Ionis Pharmaceuticals Inc | Long | Equity-common | US | $83M | 2M | 1.17 |
| Iovance Biotherapeutics Inc | Long | Equity-common | US | $56M | 7M | 0.78 |
| Ironwood Pharmaceuticals Inc | Long | Equity-common | US | $26M | 4M | 0.36 |
| iTeos Therapeutics Inc | Long | Equity-common | US | $5M | 370K | 0.08 |
| Janux Therapeutics Inc | Long | Equity-common | US | $33M | 799K | 0.47 |
| Keros Therapeutics Inc | Long | Equity-common | US | $27M | 596K | 0.38 |
| Kiniksa Pharmaceuticals International Plc | Long | Equity-common | GB | $12M | 627K | 0.16 |
| Krystal Biotech Inc | Long | Equity-common | US | $79M | 433K | 1.11 |
| Kura Oncology Inc | Long | Equity-common | US | $27M | 1M | 0.37 |
| Kymera Therapeutics Inc | Long | Equity-common | US | $28M | 940K | 0.39 |
| Madrigal Pharmaceuticals Inc | Long | Equity-common | US | $106M | 377K | 1.48 |
| MannKind Corp | Long | Equity-common | US | $19M | 4M | 0.27 |
| MiMedx Group Inc | Long | Equity-common | US | $10M | 1M | 0.14 |
| Mirum Pharmaceuticals Inc | Long | Equity-common | US | $24M | 713K | 0.34 |
| Moderna Inc | Long | Equity-common | US | $163M | 1M | 2.28 |
| Morphic Holding Inc | Long | Equity-common | US | $26M | 772K | 0.37 |
| Myriad Genetics Inc | Long | Equity-common | US | $24M | 967K | 0.33 |
| Natera Inc | Long | Equity-common | US | $184M | 2M | 2.58 |
| Neurocrine Biosciences Inc | Long | Equity-common | US | $172M | 1M | 2.41 |
| Novavax Inc | Long | Equity-common | US | $34M | 3M | 0.48 |
| Nurix Therapeutics Inc | Long | Equity-common | US | $30M | 1M | 0.42 |
| Nuvalent Inc | Long | Equity-common | US | $51M | 669K | 0.71 |
| Ocugen Inc | Long | Equity-common | US | $13M | 8M | 0.18 |
| Olema Pharmaceuticals Inc | Long | Equity-common | US | $11M | 1M | 0.16 |
| OMNIAB INC | Long | Equity-common | US | $0 | 162K | – |
| OMNIAB INC | Long | Equity-common | US | $0 | 162K | – |
| ORIC Pharmaceuticals Inc | Long | Equity-common | US | $9M | 1M | 0.12 |
| Praxis Precision Medicines Inc | Long | Equity-common | US | $18M | 428K | 0.25 |
| Protagonist Therapeutics Inc | Long | Equity-common | US | $27M | 779K | 0.38 |
| Prothena Corp PLC | Long | Equity-common | IE | $21M | 1M | 0.29 |
| PTC Therapeutics Inc | Long | Equity-common | US | $32M | 1M | 0.45 |
| Recursion Pharmaceuticals Inc | Long | Equity-common | US | $31M | 4M | 0.43 |
| Regeneron Pharmaceuticals Inc | Long | Equity-common | US | $194M | 185K | 2.73 |
| REGENXBIO Inc | Long | Equity-common | US | $12M | 1M | 0.18 |
| Relay Therapeutics Inc | Long | Equity-common | US | $13M | 2M | 0.18 |
| REVOLUTION Medicines Inc | Long | Equity-common | US | $75M | 2M | 1.05 |
| Rhythm Pharmaceuticals Inc | Long | Equity-common | US | $31M | 751K | 0.43 |
| Rocket Pharmaceuticals Inc | Long | Equity-common | US | $26M | 1M | 0.37 |
| Roivant Sciences Ltd | Long | Equity-common | BM | $91M | 9M | 1.27 |
| Sage Therapeutics Inc | Long | Equity-common | US | $14M | 1M | 0.19 |
| Sana Biotechnology Inc | Long | Equity-common | US | $19M | 4M | 0.27 |
| Sarepta Therapeutics Inc | Long | Equity-common | US | $236M | 1M | 3.31 |
| Savara Inc | Long | Equity-common | US | $6M | 1M | 0.08 |
| Scholar Rock Holding Corp | Long | Equity-common | US | $11M | 1M | 0.16 |
| Scilex Holding Co | Long | Equity-common | US | $11M | 6M | 0.16 |
| Soleno Therapeutics Inc | Long | Equity-common | US | $23M | 558K | 0.32 |
| SpringWorks Therapeutics Inc | Long | Equity-common | US | $61M | 2M | 0.85 |
| Spyre Therapeutics Inc | Long | Equity-common | US | $16M | 694K | 0.23 |
| State Street Institutional Liquid Reserves Fund (State Street Global Advisors) | Long | Short-term investment vehicle | US | $3M | 3M | 0.05 |
| State Street Navigator Securities Lending Portfolio II (State Street Global Advisors) | Long | Short-term investment vehicle | US | $531M | 531M | 7.46 |
| Stoke Therapeutics Inc | Long | Equity-common | US | $11M | 827K | 0.16 |
| Summit Therapeutics Inc | Long | Equity-common | US | $13M | 2M | 0.19 |
| Syndax Pharmaceuticals Inc | Long | Equity-common | US | $38M | 2M | 0.53 |
| Tango Therapeutics Inc | Long | Equity-common | US | $6M | 750K | 0.09 |
| TG Therapeutics Inc | Long | Equity-common | US | $62M | 3M | 0.87 |
| Travere Therapeutics Inc | Long | Equity-common | US | $16M | 2M | 0.22 |
| Twist Bioscience Corp | Long | Equity-common | US | $53M | 1M | 0.74 |
| Ultragenyx Pharmaceutical Inc | Long | Equity-common | US | $54M | 1M | 0.75 |
| United Therapeutics Corp | Long | Equity-common | US | $212M | 666K | 2.98 |
| Vaxcyte Inc | Long | Equity-common | US | $74M | 980K | 1.04 |
| Vera Therapeutics Inc | Long | Equity-common | US | $46M | 1M | 0.64 |
| Veracyte Inc | Long | Equity-common | US | $25M | 1M | 0.35 |
| Vericel Corp | Long | Equity-common | US | $31M | 684K | 0.44 |
| Vertex Pharmaceuticals Inc | Long | Equity-common | US | $187M | 399K | 2.62 |
| Verve Therapeutics Inc | Long | Equity-common | US | $7M | 2M | 0.11 |
| Viking Therapeutics Inc | Long | Equity-common | US | $184M | 3M | 2.58 |
| Vir Biotechnology Inc | Long | Equity-common | US | $13M | 2M | 0.19 |
| Viridian Therapeutics Inc | Long | Equity-common | US | $20M | 2M | 0.27 |
| Voyager Therapeutics Inc | Long | Equity-common | US | $7M | 919K | 0.10 |
| Xencor Inc | Long | Equity-common | US | $19M | 988K | 0.26 |
| Zentalis Pharmaceuticals Inc | Long | Equity-common | US | $7M | 2M | 0.10 |
Address
SPDR SERIES TRUST
One Iron Street
Boston
Massachusetts
02210
United States of America
Websites
Directors
Sandra G. Sponem
Dwight D. Churchill
Gunjan Chauhan
Carolyn M. Clancy
Carl G. Verboncoeur
James E. Ross
Clare S. Richer
Kristi L. Rowsell
Transfer Agents
State Street Bank and Trust Company
Pricing Services
Bloomberg L.P.
London Stock Exchange Group PLC
S&P Global Inc.
PricingDirect Inc.
ICE Data Services, Inc.
Custodians
State Street Bank and Trust Company
Shareholder Servicing Agents
State Street Bank and Trust Company
Admins
State Street Bank and Trust Company
SSGA Funds Management, Inc.
Brokers
N/A